Clasificación actual del carcinoma de pulmón. Consideraciones histológicas, inmunofenotípicas, moleculares y clínicas

Resumen

En los últimos años, el rápido desarrollo tecnológico y el mayor conocimiento de aspectos genéticos y moleculares en medicina han permitido un mejor enfoque en el entendimiento, diagnóstico y tratamiento de diversas enfermedades oncológicas. En relación con el carcinoma de pulmón, ha habido una significativa evolución desde sus primeras clasificaciones, puramente morfológicas, hasta la última del año 2015, en la que se integra información histológica, inmunofenotípica, genética molecular, clínica, y radiológica, lo que permite una mejor evaluación y manejo terapéutico de estos pacientes. En el presente artículo se hace un repaso desde las primeras clasificaciones del carcinoma de pulmón hasta la última, y se examinan los cambios más relevantes y la importancia de los hallazgos genéticos moleculares para un mejor enfoque clínico y terapéutico.


 

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

Citas

1. Ziogas DE, Katsios C, Roukos DH. From molecular traditional molecular biology to network oncology. Future Oncol. 2011; 7(2): 155-9.

2. Imran A, Qamar HY, Ali Q, Naeem H, Riaz M, Amin S, et al. Rol of molecular biology in cancer treatment: a review article. Iran J Public Health. 2017; 46(11): 1475-85.

3. Stahel R, Bogaerts J, Ciardiello F, De Ruysscher D, Dubsky P, Ducreux M, et al. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. Cancer Treat Rev. 2015; 41(2): 129-35.

4. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013; 108(3): 479-85.

5. O’Brien CP, Taylor SE, O’Leary JJ, Finn SP. Molecular testing in oncology: problems, pitfalls and progress. Lung Cancer. 2014; 83(3): 309-15.

6. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457): 214-8.

7. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10(8): 472-84.

8. De Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018; 7(3): 220-33.

9. Kashima J, Kitadai R, Okuma Y. Molecular and morphological profiling of lung cancer: a foundation for "next-generation" pathologists and oncologists. Cancers (Basel). 2019; 11(5).

10. Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019; 19(7): 415.

11. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158(4): 929-44.

12. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011; 32(4): 669-92.

13. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017; 7(6): 596-609.

14. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017; 17(12): 725-37.

15. Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017; 35(34): 3823-9.

16. World Health Organization. Histological typing of lung tumours. 1st ed. Geneva: Kreyberg; 1967.

17. Lamb D. Histological classification of lung cancer. Thorax. 1984; 39(3): 161-5.

18. World Health Organization. Histological typing of lung tumours. 2nd ed. Geneva: Geneva; 1981.

19. Mathews MJ. Problems in morphology and behaviour of broncho-pulmonary malignant disease. In: Israel L, Chahinian AP, eds. Lung cancer-natural, prognosis and therapy. New York: Academic Press; 1976: 23-63.

20. Carter D, Eggleston JC. Tumours of the lower respiratory tract: atlas of tumour pathology. 2nd ed. Washington D. C.: Armed Forces Institute of Pathology; 1980.

21. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005; 40(2): 90-7.

22. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Typing of lung and pleural tumors. 3a ed. Berlin: Springer; 1999.

23. Kawakami S, Sone S, Takashima S, Li F, Yang ZG, Maruyama Y, et al. Atypical adenomatous hyperplasia of the lung: correlation between high-resolution CT findings and histopathologic features. Eur Radiol. 2001; 11(5): 811-4.

24. Kushihashi T, Munechika H, Ri K, Kubota H, Ukisu R, Satoh S, et al. Bronchioloalveolar adenoma of the lung: CT-pathologic correlation. Radiology. 1994; 193(3): 789-93.

25. Kodama K, Higashiyama M, Yokouchi H, Takami K, Kuriyama K, Kusunoki Y, et al. Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years. Ann Thorac Surg. 2002; 73(2): 386-92.

26. Nakajima R, Yokose T, Kakinuma R, Nagai K, Nishiwaki Y, Ochiai A. Localized pure ground-glass opacity on high-resolution CT: histologic characteristics. J Comput Assist Tomogr. 2002; 26(3): 323-9.

27. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society: international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 8(5): 381-5.

28. Weinstein IB. Cancer: addiction to oncogenes-the Achilles heel of cancer. Science. 2002; 297(5578): 63-4.

29. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008; 14(8): 822-7.

30. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol. 2006; 24(31): 5079-90.

31. Kerr KM. Classification of lung cancer: proposals for change?. Arch Pathol Lab Med. 2012; 136(10): 1190-3.

32. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of lung tumors. J Thorac Oncol. 2015; 10(9): 1243-60.

33. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A. 2009; 106(43): 18351-6.

34. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010; 2(62): 62-93.

35. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumors independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet. 2004; 363(9411): 775-81.

36. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015; 10(9): 1243-60.

37. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013; 31(8): 992-1001.
Publicado
2019-12-05
Cómo citar
BARRIONUEVO CORNEJO, Carlos Edmundo; DUEÑAS HANCCO, Daniel Enny. Clasificación actual del carcinoma de pulmón. Consideraciones histológicas, inmunofenotípicas, moleculares y clínicas. Horizonte Médico (Lima), [S.l.], v. 19, n. 4, p. 74-83, dic. 2019. ISSN 2227-3530. Disponible en: <http://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/965>. Fecha de acceso: 19 feb. 2020 doi: https://doi.org/10.24265/horizmed.2019.v19n4.11.
Sección
ARTÍCULOS DE REVISIÓN